ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)
<p><strong>Background</strong> This randomized phase 2 trial compared the efficacy and safety of second‐line nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) with or without the addition of CC‐486 (an oral formulation of 5‐azacytidine) in patients with advanced‐stage, nonsqua...
Prif Awduron: | Morgensztern, D, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, CR, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Fasola, G, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Talbot, DC, Jin Ong, T, Govindan, R, On Behalf Of The Abound L Investigators |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
Wiley
2018
|
Eitemau Tebyg
-
ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
gan: Morgensztern, D, et al.
Cyhoeddwyd: (2017) -
Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)
gan: Morgensztern, D, et al.
Cyhoeddwyd: (2018) -
Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+
gan: Talbot, D, et al.
Cyhoeddwyd: (2018) -
Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
gan: Govindan, R, et al.
Cyhoeddwyd: (2017) -
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
gan: Daniel Morgensztern, et al.
Cyhoeddwyd: (2021-02-01)